Senzime Ab · OMXSTO:SEZI
Senzime Ab — Q1 2024 Earnings Presentation
16 slides from Senzime Ab's earnings presentation, May 7, 2024
Slide 1: Revolutionizing Perioperative Care. Q1 2024 summary
Revolutionizing Perioperative Care. Senzime develops precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our portfolio, powered by proprietary smart algorithms, generates enhanced insights to safeguard every patient's journey, from anesthe
Slide 2: Senzime Q1 2024: Record sales, once again
+ Senzime Q1 2024: Record sales, once again Q1 revenues (kSEK) 14 000 “Another quarter with record sales. We won our largest hospital deal to 12 000 date, and we stabilized our expenses. 10 000 The market outlook remains strong, catalyzed by the recently published 8 000 clinical guidelines.” 6 000 4
Slide 3: Rolling 12-month sales continues to grow
Senzime Q1 2024: Rolling 12-month sales continues to grow Net sales rolling-12 months (kSEK) Sales of TetraSens, rolling-12 months (kSEK) 44 000 24 000 40 000 22 000 20 000 36 000 18 000 32 000 16 000 28 000 14 000 24 000 12 000 20 000 10 000 16 000 8 000 12 000 6 000 8 000 4 000 4 000 2 000 0 0 Q2
Slide 4: Installed base of monitors grows, drives sales of disposable sensors
Installed base of monitors grows, drives sales of disposable sensors Total delivered base of TetraGraph-systems1 Shipped TetraSens disposable sensors (accumulated units) 2 500 300 000 2 315 TetraGraphs 250 000 2 000 delivered to date 200 000 1 500 150 000 1 000 100 000 500 50 000 0 0 Q2 2021 Q3 Q4 Q
Slide 5: TetraGraph customer (hospital) growth
TetraGraph customer (hospital) growth Number of active hospital accounts, end of period* 350 300 250 33 >330 200 New hospitals hospitals in total 150 in Q1 2024 100 50 0 Q4 2022 Q1 2023 Q2 2023 Q2 2023 Q4 2023 Q1 2024 * Excludes accounts in smaller distribution markets.
Slide 6: Utilization rate driven by leading hospital accounts
Utilization rate driven by leading hospital accounts Utilization rate (linear trend), TetraSens use per week 5,0 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Linear (All Accounts) Linear (Key accounts)
Slide 7: Senzime wins its largest US deal to date from leading Houston based university hospital system
March 2024: Senzime wins its largest US deal to date from leading Houston based university “More than 250 hospital system TetraGraph systems rolled out during 2024”
Slide 8: TetraGraph technology inside and TetraSens on patient
TetraGraph® technology inside and TetraSens on patient
Slide 9: 2024 US Commercial expansion
2024 US Commercial expansion • Expansion of the US-based sales team with additional Area Territory Managers. • Recruitment of Michael Noble as Vice President Global Marketing and joins the Executive Leadership Team. • Relocation of US headquarters from Boston to St. Louis, to enable more rapid, cost
Slide 10: Product market mix and market pricing affects Gross Margin
Product market mix and market pricing affects Gross Margin Development of COGS (MSEK) and Gross Margin rolling 12-months (%) 35,0 80,0% 69,8% 70,0% 30,0 68,6% 68,7% 68,4% 64,6% 62,0% 60,0% 25,0 57,4% 56,2% 53,7% 54,3% 53,2% 50,0% 48,2% 20,0 40,9% 40,2% 40,0% 15,0 16,9 30,0% 16,6 10,0 16,3 16,2 20,0%
Slide 11: Sales growth with operating expense control
Sales growth with operating expense control Operating expenses including currency related effects (kSEK) 50 000 45 000 40 000 35 000 32,6 MSEK 30 000 25 000 20 000 15 000 10 000 5 000 0 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Actual Adjusted
Slide 12: Strong investor base secures Senzime's long-term plans
Strong investor base secures Senzime’s long-term plans As of March 30, 2024 Number of Capital Ten largest shareholders shares (%) Crafoord family and the Crafoord Foundation 20,222,151 16,9 Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB 12,803,271 10,7 Handelsbanken Fonder 8,615,496
Slide 13: Strong start of Q2 with more important commercial wins
Strong start of Q2 with more important commerical wins >100% growth From Kids to Robots: Public tender winner: GPO Contract: Jan-April 2024: Senzime secures multiple Senzime Wins Another Major Senzime signs its first GPO Strong sales traction as we top-rated US hospital US Veterans Affairs contract
Slide 14: The Senzime 300 equation
The Senzime 300 equation 300 x 30 x 4 = 300 Hospital Average # of Average use of Million SEK in accounts TetraGraphs per TetraSens per consumable sales hospital monitor and week Goal is that Senzime shall reach sales of around 300 MSEK in 2025, reach a market share of at least 10% in its addressed m
Slide 15: We're the fastest growing medical device company on Nasdaq Stockholm
“We’re the fastest growing medical device company on Nasdaq Stockholm” >100% + + growth World-class technology Brilliant team, New clinical guidelines driving patient safety by commercial operations in in US and EU in support of perioperative, precision-based over 30 markets and strong Senzime’s pro
Slide 16: Our new vision: Revolutionizing perioperative care
Our new vision: Revolutionizing perioperative care. A world where Smart and simple. every clinician is Our mission is to safeguard every patient's journey, from anesthesia to recovery. empowered, We do this by developing user-friendly precision-based monitoring solutions, based on decades of science